{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:05:47Z","timestamp":1789617947273,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["2P30CA044579-26"],"award-info":[{"award-number":["2P30CA044579-26"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["2P30CA044579-26"],"award-info":[{"award-number":["2P30CA044579-26"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Brain metastases are a common cause of morbidity and mortality in patients with breast cancer. Local central nervous system (CNS) directed therapies are usually the first line treatment for breast cancer brain metastases (BCBM), but those must be followed by systemic therapies to achieve long-term benefit. Systemic therapy for hormone receptor (HR<jats:sup>+<\/jats:sup>) breast cancer has evolved in the last 10\u00a0years, but their role when brain metastases occur is uncertain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic review of the literature focused on management of HR<jats:sup>+<\/jats:sup> BCBM by searching Medline\/PubMed, EBSCO, and Cochrane databases. The PRISMA guidelines were used for systematic review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 807 articles identified, 98 fulfilled the inclusion criteria in their relevance to the management of HR<jats:sup>+<\/jats:sup> BCBM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Similar to brain metastases from other neoplasms, local CNS directed therapies are the first line treatment for HR<jats:sup>+<\/jats:sup> BCBM. Although the quality of evidence is low, after local therapies, our review supports the combination of targeted and endocrine therapies for both CNS and systemic management. Upon exhaustion of targeted\/endocrine therapies, case series and retrospective reports suggest that certain chemotherapy agents are active against HR<jats:sup>+<\/jats:sup> BCBM. Early phase clinical trials for HR<jats:sup>+<\/jats:sup> BCBM are ongoing, but there is a need for prospective randomized trials to guide management and improve patients\u2019 outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11060-023-04276-9","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:06:13Z","timestamp":1678277173000},"page":"45-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Systematic review of the management of brain metastases from hormone receptor positive breast cancer"],"prefix":"10.1007","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-9334","authenticated-orcid":false,"given":"Shirley","family":"Jusino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7459-7661","authenticated-orcid":false,"given":"Camilo E.","family":"Fadul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-725X","authenticated-orcid":false,"given":"Patrick","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"4276_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4276_CR2","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865\u20132872. https:\/\/doi.org\/10.1200\/JCO.2004.12.149","journal-title":"J Clin Oncol"},{"key":"4276_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","volume":"121","author":"A Darlix","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delaloge S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T (2019) Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121:991\u20131000. https:\/\/doi.org\/10.1038\/s41416-019-0619-y","journal-title":"Br J Cancer"},{"key":"4276_CR4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/1097-0142(19831215)52:12<2349::aid-cncr2820521231>3.0.co;2-b","volume":"52","author":"Y Tsukada","year":"1983","unstructured":"Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma. Autopsy study Cancer 52:2349\u20132354. https:\/\/doi.org\/10.1002\/1097-0142(19831215)52:12%3c2349::aid-cncr2820521231%3e3.0.co;2-b","journal-title":"Autopsy study Cancer"},{"key":"4276_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3389\/fonc.2020.00781","volume":"10","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Li R, Tian Y, Zhang J, Lin J, Liang Y, Xu A, Zheng R, Liu M, Yuan Y (2020) Tumor primary site and histology subtypes role in radiotherapeutic management of brain metastases. Front Oncol 10:781. https:\/\/doi.org\/10.3389\/fonc.2020.00781","journal-title":"Front Oncol"},{"key":"4276_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-020-05597-3","volume":"181","author":"M Van Mechelen","year":"2020","unstructured":"Van Mechelen M, Van Herck A, Punie K, Nevelsteen I, Smeets A, Neven P, Weltens C, Han S, Vanderstichele A, Floris G, Lobelle JP, Wildiers H (2020) Behavior of metastatic breast cancer according to subtype. Breast Cancer Res Treat 181:115\u2013125. https:\/\/doi.org\/10.1007\/s10549-020-05597-3","journal-title":"Breast Cancer Res Treat"},{"key":"4276_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.18632\/oncotarget.27453","volume":"11","author":"L Koniali","year":"2020","unstructured":"Koniali L, Hadjisavvas A, Constantinidou A, Christodoulou K, Christou Y, Demetriou C, Panayides AS, Pitris C, Pattichis CS, Zamba-Papanicolaou E, Kyriacou K (2020) Risk factors for breast cancer brain metastases: a systematic review. Oncotarget 11:650\u2013669. https:\/\/doi.org\/10.18632\/oncotarget.27453","journal-title":"Oncotarget"},{"key":"4276_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2009.24.6314","volume":"28","author":"O Graesslin","year":"2010","unstructured":"Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28:2032\u20132037. https:\/\/doi.org\/10.1200\/JCO.2009.24.6314","journal-title":"J Clin Oncol"},{"key":"4276_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.breast.2014.06.009","volume":"23","author":"C Aversa","year":"2014","unstructured":"Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, Valabrega G, Aglietta M, Montemurro F (2014) Metastatic breast cancer subtypes and central nervous system metastases. Breast 23:623\u2013628. https:\/\/doi.org\/10.1016\/j.breast.2014.06.009","journal-title":"Breast"},{"key":"4276_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, Dhaliwal AJ, Sahgal A, Das S, Chan KK, Jerzak KJ (2021) The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol 23:894\u2013904. https:\/\/doi.org\/10.1093\/neuonc\/noaa285","journal-title":"Neuro Oncol"},{"key":"4276_CR11","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Franzoi MAB, Kirshner JJ, Krop IE, Patt DA, Perlmutter J, Giordano SH (2022) Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 40:2636\u20132655. https:\/\/doi.org\/10.1200\/JCO.22.00520","journal-title":"J Clin Oncol"},{"key":"4276_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","volume":"3","author":"AM Martin","year":"2017","unstructured":"Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA (2017) Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol 3:1069\u20131077. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0001","journal-title":"JAMA Oncol"},{"key":"4276_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4276_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.21.02314","volume":"40","author":"MA Vogelbaum","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492\u2013516. https:\/\/doi.org\/10.1200\/JCO.21.02314","journal-title":"J Clin Oncol"},{"key":"4276_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199002223220802","volume":"322","author":"RA Patchell","year":"1990","unstructured":"Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494\u2013500. https:\/\/doi.org\/10.1056\/NEJM199002223220802","journal-title":"N Engl J Med"},{"key":"4276_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.410330605","volume":"33","author":"CJ Vecht","year":"1993","unstructured":"Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583\u2013590. https:\/\/doi.org\/10.1002\/ana.410330605","journal-title":"Ann Neurol"},{"key":"4276_CR17","doi-asserted-by":"publisher","first-page":"20170099","DOI":"10.1259\/bjr.20170099","volume":"90","author":"YM Han","year":"2017","unstructured":"Han YM, Cai G, Chai WM, Xu C, Cao L, Ou D, Chen JY, Kirova YM (2017) Radiological distribution of brain metastases and its implication for the hippocampus avoidance in whole brain radiotherapy approach. Br J Radiol 90:20170099. https:\/\/doi.org\/10.1259\/bjr.20170099","journal-title":"Br J Radiol"},{"key":"4276_CR18","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","volume":"32","author":"V Gondi","year":"2014","unstructured":"Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32:3810\u20133816. https:\/\/doi.org\/10.1200\/JCO.2014.57.2909","journal-title":"J Clin Oncol"},{"key":"4276_CR19","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/not114","volume":"15","author":"PD Brown","year":"2013","unstructured":"Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D, Radiation Therapy Oncology G (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429\u20131437. https:\/\/doi.org\/10.1093\/neuonc\/not114","journal-title":"Neuro Oncol"},{"key":"4276_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.clon.2020.02.007","volume":"32","author":"TG Wilson","year":"2020","unstructured":"Wilson TG, Robinson T, MacFarlane C, Spencer T, Herbert C, Wade L, Reed H, Braybrooke JP (2020) Treating brain metastases from breast cancer: outcomes after stereotactic radiosurgery. Clin Oncol (R Coll Radiol) 32:390\u2013396. https:\/\/doi.org\/10.1016\/j.clon.2020.02.007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"4276_CR21","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1200\/JCO.2013.54.0955","volume":"32","author":"N Ramakrishna","year":"2014","unstructured":"Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU (2014) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2100\u20132108. https:\/\/doi.org\/10.1200\/JCO.2013.54.0955","journal-title":"J Clin Oncol"},{"key":"4276_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.prro.2011.12.004","volume":"2","author":"MN Tsao","year":"2012","unstructured":"Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2:210\u2013225. https:\/\/doi.org\/10.1016\/j.prro.2011.12.004","journal-title":"Pract Radiat Oncol"},{"key":"4276_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3171\/2012.4.JNS11870","volume":"117","author":"R Grandhi","year":"2012","unstructured":"Grandhi R, Kondziolka D, Panczykowski D, Monaco EA 3rd, Kano H, Niranjan A, Flickinger JC, Lunsford LD (2012) Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases. J Neurosurg 117:237\u2013245. https:\/\/doi.org\/10.3171\/2012.4.JNS11870","journal-title":"J Neurosurg"},{"key":"4276_CR24","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037\u20131044. https:\/\/doi.org\/10.1016\/S1470-2045(09)70263-3","journal-title":"Lancet Oncol"},{"key":"4276_CR25","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","volume":"59","author":"SL Groenland","year":"2020","unstructured":"Groenland SL, Martinez-Chavez A, van Dongen MGJ, Beijnen JH, Schinkel AH, Huitema ADR, Steeghs N (2020) Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clin Pharmacokinet 59:1501\u20131520. https:\/\/doi.org\/10.1007\/s40262-020-00930-x","journal-title":"Clin Pharmacokinet"},{"key":"4276_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdx797","volume":"29","author":"NC Turner","year":"2018","unstructured":"Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Dieras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA (2018) Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 29:669\u2013680. https:\/\/doi.org\/10.1093\/annonc\/mdx797","journal-title":"Ann Oncol"},{"key":"4276_CR27","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O\u2019Shaughnessy J (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738\u20131748. https:\/\/doi.org\/10.1056\/NEJMoa1609709","journal-title":"N Engl J Med"},{"key":"4276_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O\u2019Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541\u20131547. https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"key":"4276_CR29","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465\u20132472. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"key":"4276_CR30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 32:1015\u20131024. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.353","journal-title":"Ann Oncol"},{"key":"4276_CR31","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O\u2019Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J (2017) MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(\u2212) metastatic breast cancer. Clin Cancer Res 23:5218\u20135224. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0754","journal-title":"Clin Cancer Res"},{"key":"4276_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"},{"key":"4276_CR33","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638\u20133646. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155","journal-title":"J Clin Oncol"},{"key":"4276_CR34","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","volume":"26","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Dieras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK (2020) A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 26:5310\u20135319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1764","journal-title":"Clin Cancer Res"},{"key":"4276_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.breast.2020.11.019","volume":"54","author":"I Troussier","year":"2020","unstructured":"Troussier I, Canova C, Klausner G (2020) Complete response of leptomeningeal carcinomatosis secondary to breast cancer. Breast 54:328\u2013330. https:\/\/doi.org\/10.1016\/j.breast.2020.11.019","journal-title":"Breast"},{"key":"4276_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1159\/000504405","volume":"15","author":"I Radke","year":"2020","unstructured":"Radke I, von Wahlde MK, Schulke C, Tio J (2020) Ribociclib in breast cancer brain metastases: a case report. Breast Care (Basel) 15:543\u2013547. https:\/\/doi.org\/10.1159\/000504405","journal-title":"Breast Care (Basel)"},{"key":"4276_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.18632\/oncotarget.27904","volume":"12","author":"I Schlam","year":"2021","unstructured":"Schlam I, Tolaney SM (2021) Is there a role for CDK 4\/6 inhibitors in breast cancer brain metastases? Oncotarget 12:873\u2013875. https:\/\/doi.org\/10.18632\/oncotarget.27904","journal-title":"Oncotarget"},{"key":"4276_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1089\/andro.2021.0007","volume":"2","author":"I Azcoitia","year":"2021","unstructured":"Azcoitia I, Mendez P, Garcia-Segura LM (2021) Aromatase in the human brain. Androg Clin Res Ther 2:189\u2013202. https:\/\/doi.org\/10.1089\/andro.2021.0007","journal-title":"Androg Clin Res Ther"},{"key":"4276_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.breast.2005.07.006","volume":"15","author":"R Madhup","year":"2006","unstructured":"Madhup R, Kirti S, Bhatt ML, Srivastava PK, Srivastava M, Kumar S (2006) Letrozole for brain and scalp metastases from breast cancer\u2014a case report. Breast 15:440\u2013442. https:\/\/doi.org\/10.1016\/j.breast.2005.07.006","journal-title":"Breast"},{"key":"4276_CR40","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00701-008-1576-z","volume":"150","author":"S Goyal","year":"2008","unstructured":"Goyal S, Puri T, Julka PK, Rath GK (2008) Excellent response to letrozole in brain metastases from breast cancer. Acta Neurochir (Wien) 150:613\u2013614. https:\/\/doi.org\/10.1007\/s00701-008-1576-z. (discussion 614-615)","journal-title":"Acta Neurochir (Wien)"},{"key":"4276_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1524-4741.2009.00756.x","volume":"15","author":"K Ito","year":"2009","unstructured":"Ito K, Ito T, Okada T, Watanabe T, Gomi K, Kanai T, Mochizuki Y, Amano J (2009) A case of brain metastases from breast cancer that responded to anastrozole monotherapy. Breast J 15:435\u2013437. https:\/\/doi.org\/10.1111\/j.1524-4741.2009.00756.x","journal-title":"Breast J"},{"key":"4276_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-215525","author":"MM Almajed","year":"2016","unstructured":"Almajed MM, Esfahani K, Pelmus M, Panasci L (2016) Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2016-215525","journal-title":"BMJ Case Rep"},{"key":"4276_CR43","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clbc.2016.02.013","volume":"16","author":"P Saha","year":"2016","unstructured":"Saha P, Amico AL, Olopade OI (2016) Long-term disease-free survival in a young patient with hormone receptor-positive breast cancer and oligometastatic disease in the brain. Clin Breast Cancer 16:e61-63. https:\/\/doi.org\/10.1016\/j.clbc.2016.02.013","journal-title":"Clin Breast Cancer"},{"key":"4276_CR44","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","volume":"26","author":"NC Turner","year":"2020","unstructured":"Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, Robertson JFR, Gradishar W, Piccart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK (2020) ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 26:5172\u20135177. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0224","journal-title":"Clin Cancer Res"},{"key":"4276_CR45","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1158\/1078-0432.CCR-18-1968","volume":"25","author":"ES Bergen","year":"2019","unstructured":"Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R (2019) Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. Clin Cancer Res 25:2737\u20132744. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1968","journal-title":"Clin Cancer Res"},{"key":"4276_CR46","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6","volume":"89","author":"A Howell","year":"2000","unstructured":"Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, \u201cpure\u201d antiestrogen. Cancer 89:817\u2013825. https:\/\/doi.org\/10.1002\/1097-0142(20000815)89:4%3c817::aid-cncr14%3e3.0.co;2-6","journal-title":"Cancer"},{"key":"4276_CR47","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/OTT.S188143","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Sun B, Liu C, Shi S, Ding L, Liu J, Wu S (2019) Brain metastases from breast cancer may respond to endocrine therapy: report of two cases. Onco Targets Ther 12:1389\u20131393. https:\/\/doi.org\/10.2147\/OTT.S188143","journal-title":"Onco Targets Ther"},{"key":"4276_CR48","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.2147\/OTT.S170736","volume":"11","author":"O Rusz","year":"2018","unstructured":"Rusz O, Koszo R, Dobi A, Csenki M, Valicsek E, Nikolenyi A, Uhercsak G, Cserhati A, Kahan Z (2018) Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series. Onco Targets Ther 11:5459\u20135463. https:\/\/doi.org\/10.2147\/OTT.S170736","journal-title":"Onco Targets Ther"},{"key":"4276_CR49","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388:2997\u20133005. https:\/\/doi.org\/10.1016\/S0140-6736(16)32389-3","journal-title":"Lancet"},{"key":"4276_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"RH Jones","year":"2020","unstructured":"Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ (2020) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 21:345\u2013357. https:\/\/doi.org\/10.1016\/S1470-2045(19)30817-4","journal-title":"Lancet Oncol"},{"key":"4276_CR51","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529. https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"4276_CR52","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10549-018-4852-5","volume":"171","author":"AED Van Swearingen","year":"2018","unstructured":"Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK (2018) LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat 171:637\u2013648. https:\/\/doi.org\/10.1007\/s10549-018-4852-5","journal-title":"Breast Cancer Res Treat"},{"key":"4276_CR53","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.21037\/atm-21-3840","volume":"9","author":"XB Shen","year":"2021","unstructured":"Shen XB, Li GL, Zheng YB, Chen ZH, Cao WM, Wang XJ, Shao XY (2021) Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study. Ann Transl Med 9:1334. https:\/\/doi.org\/10.21037\/atm-21-3840","journal-title":"Ann Transl Med"},{"key":"4276_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00403","author":"F Batalini","year":"2020","unstructured":"Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM (2020) Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.19.00403","journal-title":"JCO Precis Oncol"},{"key":"4276_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221096413","author":"J Miller","year":"2022","unstructured":"Miller J, Armgardt E, Svoboda A (2022) The efficacy and safety of alpelisib in breast cancer: a real-world analysis. J Oncol Pharmacy Pract. https:\/\/doi.org\/10.1177\/10781552221096413","journal-title":"J Oncol Pharmacy Pract"},{"key":"4276_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106177","volume":"173","author":"YK Song","year":"2022","unstructured":"Song YK, Kim MJ, Kim MS, Lee JH, Chung SJ, Song JS, Chae YJ, Lee KR (2022) Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice. Eur J Pharm Sci 173:106177. https:\/\/doi.org\/10.1016\/j.ejps.2022.106177","journal-title":"Eur J Pharm Sci"},{"key":"4276_CR57","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"key":"4276_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","volume":"120","author":"M Robson","year":"2019","unstructured":"Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P (2019) Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 120:20\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2019.06.023","journal-title":"Eur J Cancer"},{"key":"4276_CR59","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D\u2019Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE (2020) TBCRC 048: Phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38:4274\u20134282. https:\/\/doi.org\/10.1200\/JCO.20.02151","journal-title":"J Clin Oncol"},{"key":"4276_CR60","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676. https:\/\/doi.org\/10.1056\/NEJMoa072113","journal-title":"N Engl J Med"},{"key":"4276_CR61","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239\u20133247. https:\/\/doi.org\/10.1200\/JCO.2008.21.6457","journal-title":"J Clin Oncol"},{"key":"4276_CR62","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O\u2019Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252\u20131260. https:\/\/doi.org\/10.1200\/JCO.2010.28.0982","journal-title":"J Clin Oncol"},{"key":"4276_CR63","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, Masuda N, Ro J, Denduluri N, Hubeaux S, Quah C, Bais C, O\u2019Shaughnessy J (2017) Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer 70:146\u2013155. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.024","journal-title":"Eur J Cancer"},{"key":"4276_CR64","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"AM Brufsky","year":"2011","unstructured":"Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O\u2019Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286\u20134293. https:\/\/doi.org\/10.1200\/JCO.2010.34.1255","journal-title":"J Clin Oncol"},{"key":"4276_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-020-01372-w","volume":"22","author":"JP Leone","year":"2020","unstructured":"Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, Younger J, Pinho MC, Sorensen AG, Gerstner ER, Harris G, Krop IE, Morganstern D, Sohl J, Hu J, Kasparian E, Winer EP, Lin NU (2020) Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res 22:131. https:\/\/doi.org\/10.1186\/s13058-020-01372-w","journal-title":"Breast Cancer Res"},{"key":"4276_CR66","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-14-2075","volume":"21","author":"YS Lu","year":"2015","unstructured":"Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL, Taiwan Breast Cancer C (2015) Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res 21:1851\u20131858. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2075","journal-title":"Clin Cancer Res"},{"key":"4276_CR67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14694\/EDBK_175338","volume":"37","author":"NU Lin","year":"2017","unstructured":"Lin NU, Gaspar LE, Soffietti R (2017) Breast cancer in the central nervous system: multidisciplinary considerations and management. Am Soc Clin Oncol Educ Book 37:45\u201356. https:\/\/doi.org\/10.14694\/EDBK_175338. (10.1200\/EDBK_175338)","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4276_CR68","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/1097-0142(19860815)58:4<832::aid-cncr2820580404>3.0.co;2-w","volume":"58","author":"D Rosner","year":"1986","unstructured":"Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832\u2013839. https:\/\/doi.org\/10.1002\/1097-0142(19860815)58:4%3c832::aid-cncr2820580404%3e3.0.co;2-w","journal-title":"Cancer"},{"key":"4276_CR69","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/cncr.22127","volume":"107","author":"E Rivera","year":"2006","unstructured":"Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T (2006) Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348\u20131354. https:\/\/doi.org\/10.1002\/cncr.22127","journal-title":"Cancer"},{"key":"4276_CR70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/00000421-200108000-00026","volume":"24","author":"ML Wang","year":"2001","unstructured":"Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL (2001) Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol 24:421\u2013424. https:\/\/doi.org\/10.1097\/00000421-200108000-00026","journal-title":"Am J Clin Oncol"},{"key":"4276_CR71","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11060-005-9044-6","volume":"78","author":"AB Lassman","year":"2006","unstructured":"Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ (2006) Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78:255\u2013260. https:\/\/doi.org\/10.1007\/s11060-005-9044-6","journal-title":"J Neurooncol"},{"key":"4276_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1023\/a:1005835430489","volume":"35","author":"N Vinolas","year":"1997","unstructured":"Vinolas N, Graus F, Mellado B, Caralt L, Estape J (1997) Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors. J Neurooncol 35:145\u2013148. https:\/\/doi.org\/10.1023\/a:1005835430489","journal-title":"J Neurooncol"},{"key":"4276_CR73","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","volume":"124","author":"C Bailleux","year":"2021","unstructured":"Bailleux C, Eberst L, Bachelot T (2021) Treatment strategies for breast cancer brain metastases. Br J Cancer 124:142\u2013155. https:\/\/doi.org\/10.1038\/s41416-020-01175-y","journal-title":"Br J Cancer"},{"key":"4276_CR74","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1124\/mol.59.6.1542","volume":"59","author":"JF Mata","year":"2001","unstructured":"Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ, Pastor-Anglada M (2001) Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59:1542\u20131548. https:\/\/doi.org\/10.1124\/mol.59.6.1542","journal-title":"Mol Pharmacol"},{"key":"4276_CR75","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","volume":"85","author":"M Ekenel","year":"2007","unstructured":"Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE (2007) Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223\u2013227. https:\/\/doi.org\/10.1007\/s11060-007-9409-0","journal-title":"J Neurooncol"},{"key":"4276_CR76","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/1097-0142(19920215)69:4<972::aid-cncr2820690423>3.0.co;2-p","volume":"69","author":"W Boogerd","year":"1992","unstructured":"Boogerd W, Dalesio O, Bais EM, van der Sande JJ (1992) Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69:972\u2013980. https:\/\/doi.org\/10.1002\/1097-0142(19920215)69:4%3c972::aid-cncr2820690423%3e3.0.co;2-p","journal-title":"Cancer"},{"key":"4276_CR77","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","volume":"85","author":"V Franciosi","year":"1999","unstructured":"Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S (1999) Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85:1599\u20131605","journal-title":"Cancer"},{"key":"4276_CR78","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/annonc\/mdl056","volume":"17","author":"ME Trudeau","year":"2006","unstructured":"Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada\u2014Clinical Trials Group (NCIC-CTG). Ann Oncol 17:952\u2013956. https:\/\/doi.org\/10.1093\/annonc\/mdl056","journal-title":"Ann Oncol"},{"key":"4276_CR79","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11060-014-1378-5","volume":"117","author":"B Linot","year":"2014","unstructured":"Linot B, Campone M, Augereau P, Delva R, Abadie-Lacourtoisie S, Nebout-Mesgouez N, Capitain O (2014) Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 117:253\u2013259. https:\/\/doi.org\/10.1007\/s11060-014-1378-5","journal-title":"J Neurooncol"},{"key":"4276_CR80","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.2217\/fon-2021-0300","volume":"17","author":"A Fabi","year":"2021","unstructured":"Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nistico C, Carapella C, Ruda R, Pace A, Maschio M, Telera S, Cognetti F, Aino (2021) Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. Future Oncol 17:3445\u20133456. https:\/\/doi.org\/10.2217\/fon-2021-0300","journal-title":"Future Oncol"},{"key":"4276_CR81","first-page":"1250","volume":"14","author":"YH Kai Xu","year":"2021","unstructured":"Kai Xu YH, Yao J, Zhong Xu, He X (2021) Whole-brain radiotherapy and chemotherapy in the treatment of patients with breast cancer and brain metastases. Int J Clin Exp Med 14:1250\u20131257","journal-title":"Int J Clin Exp Med"},{"key":"4276_CR82","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1093\/annonc\/mdu465","volume":"25","author":"C Levy","year":"2014","unstructured":"Levy C, Allouache D, Lacroix J, Dugue AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X (2014) REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol 25:2351\u20132356. https:\/\/doi.org\/10.1093\/annonc\/mdu465","journal-title":"Ann Oncol"},{"key":"4276_CR83","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.breast.2021.10.001","volume":"60","author":"KN Kim","year":"2021","unstructured":"Kim KN, Shah P, Clark A, Freedman GM, Dastgheyb S, Barsky AR, Dreyfuss AD, Taunk NK (2021) Safety of cyclin-dependent kinase4\/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. Breast 60:163\u2013167. https:\/\/doi.org\/10.1016\/j.breast.2021.10.001","journal-title":"Breast"},{"key":"4276_CR84","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos PK, Lee EQ, Cohen JV, Tolaney SM, Lin NU, Wang N, Chukwueke U, White MD, Nayyar N, Kim A, Alvarez-Breckenridge C, Krop I, Mahar MK, Bertalan MS, Shaw B, Mora JL, Goss N, Subramanian M, Nayak L, Dietrich J, Forst DA, Nahed BV, Batchelor TT, Shih HA, Gerstner ER, Moy B, Lawrence D, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ (2020) Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 26:1280\u20131284. https:\/\/doi.org\/10.1038\/s41591-020-0918-0","journal-title":"Nat Med"},{"key":"4276_CR85","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822","journal-title":"Clin Cancer Res"},{"key":"4276_CR86","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107:1039\u20131046. https:\/\/doi.org\/10.1111\/cas.12966","journal-title":"Cancer Sci"},{"key":"4276_CR87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"4276_CR88","unstructured":"Hurvitz S ea (2021) Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer., 2021 San Antonio Breast Cancer Symposium"},{"key":"4276_CR89","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","volume":"26","author":"P Kumthekar","year":"2020","unstructured":"Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N (2020) ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res 26:2789\u20132799. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3258","journal-title":"Clin Cancer Res"},{"key":"4276_CR90","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1158\/1078-0432.CCR-15-2160","volume":"22","author":"CX Ma","year":"2016","unstructured":"Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ (2016) A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22:2650\u20132658. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2160","journal-title":"Clin Cancer Res"},{"key":"4276_CR91","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00432-012-1358-0","volume":"139","author":"C Bachmann","year":"2013","unstructured":"Bachmann C, Grischke EM, Fehm T, Staebler A, Schittenhelm J, Wallwiener D (2013) CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary. J Cancer Res Clin Oncol 139:551\u2013556. https:\/\/doi.org\/10.1007\/s00432-012-1358-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"4276_CR92","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00432-013-1511-4","volume":"139","author":"C Bachmann","year":"2013","unstructured":"Bachmann C, Grischke EM, Staebler A, Schittenhelm J, Wallwiener D (2013) Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer. J Cancer Res Clin Oncol 139:1909\u20131916. https:\/\/doi.org\/10.1007\/s00432-013-1511-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"4276_CR93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-017-4526-8","volume":"167","author":"O Kaidar-Person","year":"2018","unstructured":"Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert BG, Vieites B, Limon D, Kurman N, Ko K, Yu JB, Chiang V, Poortmans P, Zagar T (2018) Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Res Treat 167:479\u2013483. https:\/\/doi.org\/10.1007\/s10549-017-4526-8","journal-title":"Breast Cancer Res Treat"},{"key":"4276_CR94","doi-asserted-by":"publisher","first-page":"435","DOI":"10.47162\/RJME.62.2.09","volume":"62","author":"A Sava","year":"2021","unstructured":"Sava A, Costea CF, Vatavu R, Grigore M, Turliuc MD, Dumitrescu GF, Eva L, Motoc AGM, Stan CI, Gavril LC, Scripcariu SI (2021) Brain metastases originating in breast cancer: clinical-pathological analysis and immunohistochemical profile. Rom J Morphol Embryol 62:435\u2013444. https:\/\/doi.org\/10.47162\/RJME.62.2.09","journal-title":"Rom J Morphol Embryol"},{"key":"4276_CR95","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.21873\/anticanres.11894","volume":"37","author":"M Timmer","year":"2017","unstructured":"Timmer M, Werner JM, Rohn G, Ortmann M, Blau T, Cramer C, Stavrinou P, Krischek B, Mallman P, Goldbrunner R (2017) Discordance and conversion rates of progesterone-, estrogen-, and HER2\/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res 37:4859\u20134865. https:\/\/doi.org\/10.21873\/anticanres.11894","journal-title":"Anticancer Res"},{"key":"4276_CR96","doi-asserted-by":"publisher","first-page":"vdab010","DOI":"10.1093\/noajnl\/vdab010","volume":"3","author":"R Kotecha","year":"2021","unstructured":"Kotecha R, Tonse R, Rubens M, McDermott MW, Odia Y, Appel H, Mehta MP (2021) Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv 3:vdab010. https:\/\/doi.org\/10.1093\/noajnl\/vdab010","journal-title":"Neurooncol Adv"},{"key":"4276_CR97","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaoncol.2016.5630","volume":"3","author":"N Priedigkeit","year":"2017","unstructured":"Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, Thomas R, Leone JP, Lucas PC, Bhargava R, Hamilton RL, Chmielecki J, Puhalla SL, Davidson NE, Oesterreich S, Brufsky AM, Young L, Lee AV (2017) Intrinsic subtype switching and acquired ERBB2\/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol 3:666\u2013671. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5630","journal-title":"JAMA Oncol"},{"key":"4276_CR98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-014-3090-8","volume":"147","author":"N Niikura","year":"2014","unstructured":"Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H (2014) Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103\u2013112. https:\/\/doi.org\/10.1007\/s10549-014-3090-8","journal-title":"Breast Cancer Res Treat"},{"key":"4276_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102787","author":"E Laakmann","year":"2020","unstructured":"Laakmann E, Witzel I, Neunhoffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, Mundhenke C, Polasik A, Lubbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Muller V (2020) Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12102787","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04276-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04276-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T08:12:05Z","timestamp":1679991125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04276-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["4276"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04276-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}